49
Participants
Start Date
March 31, 2004
Primary Completion Date
June 30, 2006
Study Completion Date
June 30, 2006
G-CSF Plus Plerixafor
Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
University of Arkansas for Medical Sciences, Little Rock
UCLA School of Medicine, Loa Angeles
Loyola University Medical Center, Maywood
University of Iowa, Iowa City
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Roswell Park Cancer Institute, Buffalo
Thomas Jefferson University, Philadelphia
Collaborators (1)
AnorMED
INDUSTRY
Genzyme, a Sanofi Company
INDUSTRY